54results about How to "Improve targeting selectivity" patented technology

The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

The present invention relates to a novel siRNA structure and the use thereof, and more particularly to a double-stranded siRNA molecule comprising an antisense strand and a sense strand, wherein the siRNA molecule has at least one single nucleotide bulge formed by introducing a single nucleotide into the antisense strand, particularly at position 2 from the 5′ end, and to a method of using the same to silence a target gene. The siRNA molecule of the invention shows high target gene silencing efficiency while minimizing off-target effects caused by the antisense strand, and thus has improved target selectivity. Accordingly, the siRNA molecule of the invention can be substituted for conventional siRNA molecules and can be widely be used in siRNA-based gene silencing techniques, including gene therapy.

The invention relates to an ester hydrogenation catalyst and a preparation method and application thereof. The catalyst contains 5-30% (wt) of an active ingredient, 0.1-2.5% (wt) of an assistant and a carrier, wherein the active ingredient is a Cu-Ag alloy; the assistant includes one or more of B, C, N, F, Cl or Br; the carrier is a composite oxide of r-Al2O3 and SiO2, the mass ratio of Cu to Ag is (0.1-10):1 and the mass ratio of Al to Si in the carrier is (0.1-2):1. The catalyst is prepared by adopting a coprecipitation method, and is mainly applied to reaction of ester-hydrogenated alcohol. Compared with the prior art, the ester hydrogenation catalyst has the characteristics of high activity, high orientation selectivity and good stability, and is especially suitable for industrial application.

The invention relates to the fields of drug residue monitoring and analyzing technology and new materials, in particular to an MIP-SPME (molecularly imprinted polymer-solid phase microextraction) fiber for selectively identifying and measuring triazole pesticides, an extraction platform and an application. The MIP-SPME fiber comprises a substrate material and a tebuconazole-MIP coating located on the surface of the substrate material, wherein the substrate material is a metal material, and the tebuconazole-MIP coating is immobilized on the surface of the substrate material in a mode of electrochemical polymerization. The SPME coating prepared with the in-situ electrochemical polymerization method has the characteristics of controllable film thickness and homogeneity of preparation; a metal Pt wire is adopted as the substrate material, so that the defect that a quartz fiber is easy to break is overcome; meanwhile, with the introduction of the molecular imprinting technology, the target selectivity of the SPME is greatly improved.

The present invention relates to a docetaxel nanometer lipid injection. The invention also relates to a method for preparing the docetaxel nanometer lipid injection. The invention further relates to the application of the docetaxel nanometer lipid injection for preparing medicament for treating a tumor. The nanometer preparation of the invention is capable of prolonging the medicament action time, conveying the medicament with a target, reducing the administration dose under the precondition of ensuring the medicament action, alleviating or avoiding medicament toxin and side effects, improving the medicament action stability, and being benefited for the medicament storage, thus it is capable of implementing the development of the medicament which has advantages in the aspects of a high yield, automatization, large scale, low cost, convenient carry and storage, small dose and low side-effect.

A method for producing an unsaturated nitrile by subjecting propane to a vapor-phase catalytic ammoxidation reaction using a fluidized bed reactor in the presence of a composite oxide catalyst containing Mo, V, and Nb, the method comprising the step of:

• • adding a tungsten compound into the fluidized bed reactor to adjust a molar ratio (W/Mo ratio) of tungsten contained in a tungsten compound to molybdenum contained in the composite oxide catalyst that exist within the fluidized bed reactor so that the molar ratio is in the range of 0.0001 to 0.1.

An LNA (2) is directly connected to a loop antenna (1), and a variable BPF (3), the passed frequency band of which is adapted to be variable, is connected in a stage following the LNA (2). In this way, the variable BPF (3) is used to configure a variable tuning circuit exhibiting a high Q-value without using any impedance conversion transformer between the loop antenna (1) and the LNA (2), whereby almost all of the constituent elements of the tuner part can be integrated in an IC chip (10) and further the variable tuning can maintain an excellent selectivity of a target frequency.

A fluidized-bed catalyst suitable for the production of halogenated aromatic nitriles includes an active component and a support. The active component is a complex having the following composition expressed in atomic ratio:

VP_aCr_bA_cM_dO_x,

• • wherein A represents at least one metal selected from the group consisting of alkali metals and alkaline earth metals; M represents at least one element selected from the group consisting of Ti, Zr, Hf, La, Ce, Nb, Mo, W, Co, Zn, Fe, Ni, B, Sb, Bi, As, Ga, Ge, Sn, and In; in the XRD spectrum of the catalyst, diffraction peaks are present at 2θ=27.8±0.5° and 2θ=13.8±0.5°, and the ratio of the height (I₁) of the diffraction peak at 2θ=27.8±0.5° to the height (I₂) of the diffraction peak at 2θ=13.8±0.5° is 3.5-6, i.e. I₁:I₂=3.5-6.

The invention discloses a co-immobilized TNF-a/IFN-g/DOX/FA/Fe3O4-OA magnetic targeted nanoparticle as well as the preparation method and application thereof. In the invention, three high-efficiency anti-cancer medicines which are tumour necrosis factor-a, interferon-g and adriamycin as well as cancer cell targeted folic acid are connected with a photoactive group; the three photoactive tumour necrosis factor-a, interferon-g and adriamycin as well as the folic acid are connected to a nano-carrier via an amidation reaction by adopting a photochemical fixation method to obtain a magnetic nanometre compound particle with a multilayer structure and a plurality of functions. The co-immobilized TNF-a/IFN-g/DOX/FA/Fe3O4-OA magnetic targeted nanoparticle of the invention has a good effect to externally inhibit HeLa cell growth, and has no obvious toxic and side effects to normal tissues, which can be used for preparing a medicine treating tumour.

The invention discloses substituted porphyrin gold (III) compounds with anticancer activity and a preparation method thereof, belonging to the technical field of medicament preparation. The preparation method comprises the following steps of: coordinating substituted tetraphenylporphyrin and gold to generate a substituted tetraphenyl porphyrin gold (III) compound; and introducing a targeting group onto a porphyrin ring to enhance the targeting selectivity of porphyrin gold, lower the toxicity of the porphyrin gold, further improve the performance of the porphyrin gold (III) compound and preserve or enhance the anticancer activity of the porphyrin gold (III) compound. As proved by in-vitro detection data of an S180 cell, the compound synthesized with the method has a remarkable suppressingfunction, the highest suppression ratio up to 92.863 percent higher than that of tetraphenyl porphyrin gold (III) serving as a lead compound and a weak suppressing function on normal cells. The preparation method is scientific and reasonable; and the prepared substituted porphyrin gold (III) compounds have high anticancer activity, a small toxic or side effect and a simple, convenient, and practical preparation process, and is suitable for industrial mass production.

The invention provides a biotin-podophyllotoxin esterified derivative represented as the general formula (I), pharmaceutical composition taking compounds as active ingredients, as well as applications of the biotin-podophyllotoxin esterified derivative in preparing antitumor drugs and inhibitors. Activity screening proves that the biotin-podophyllotoxin esterified derivative represented as the general formula (I) has better antitumor activity. Meanwhile, a preparation method of the compounds is provided and comprises the following steps: podophyllotoxin is taken as a lead compound, structures of hydroxyl at the 4 site and methoxyl at the 4' site are modified, and a series of compounds are synthesized through connection of different chains between biotin and podophyllotoxin. According to the invention, biotin which is necessary for cell growth is used for structure modification on podophyllotoxin, cancer cell targeting selectivity of a modifier is improved, selective distribution toward cancer cells is realized, and better treatment effect can be achieved. Meanwhile, biotin is soluble in water, and the water solubility problem of drugs can be solved by introducing biotin into podophyllotoxin molecules.

Disclosed are a catalyst for preparing hydrocarbons from carbon dioxide by one-step hydrogenation and a method for preparing same. The catalyst includes nano-metal oxides and hierarchical zeolites, where the mass fraction of the nano-metal oxides in the catalyst is 10%-90%, and the mass fraction of the hierarchical zeolites in the catalyst is 10%-90%. The catalyst has excellent catalytic performance, good reaction stability and high selectivity for desired products, and in the hydrocarbons, C₂⁼-C₄⁼ reach up to 80%, C₅₊ reach up to 80%, and aromatics reach up to 65%.

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (FcγRIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

The invention discloses a nano-selenium loaded VP1 gene siRNA. The nano-selenium loaded VP1 gene siRNA is small in particle size, and can avoid an immune system to reach smallest capillaries, so thatresidence time is prolonged in a bloodstream; and the nano-selenium loaded VP1 gene siRNA has the characteristics of high target selectivity and long half-life. The genetic locus interfered by the siRNA is nucleotide of the 157th; and the siRNA sequence is: Sense 5'-ggcaucaucaaaugcuagutt-3', Antisense 5'-acuagcauuugaugaugcctt-3'. The invention also provides a preparation method and an applicationof the nano-selenium loaded VP1 gene siRNA.